🔴 Xenetic Biosciences is trading 6.4% down today as Santersus shareholders would own 85%

Xenetic Biosciences is trading 6.4% down now at $2.30 as investors continue repricing the proposed all-stock acquisition of Santersus AG.

• Under the announced terms, Santersus shareholders would receive approximately 85% of the combined company.
• Current Xenetic shareholders would retain about 15% ownership on a fully diluted basis.
• The transaction requires shareholder approval and is expected to transform the company’s business and ownership structure.